bluebird bio Inc. [BLUE] moved down -7.05: Why It’s Important

bluebird bio Inc. [NASDAQ: BLUE] closed the trading session at $7.78 on 12/15/22. The day’s price range saw the stock hit a low of $7.70, while the highest price level was $8.41. The company report on December 10, 2022 that New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Findings from clinical studies (N=63) through eight years of long-term follow-up (n=3) continue to support ZYNTEGLO as a potentially curative one-time gene therapy for patients with beta-thalassemia who require regular red blood cell (RBC) transfusions through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels.

Detailed investigations affirm that two cases of anemia in patients with sickle cell disease following treatment with lovo-cel in HGB-206 Group C are consistent with alpha-thalassemia trait.

The stocks have a year to date performance of -22.12 percent and weekly performance of -0.77 percent. The stock has been moved at 154.25 percent over the last six months. The stock has performed 1.04 percent around the most recent 30 days and changed 22.71 percent over the most recent 3-months.

If compared to the average trading volume of 5.26M shares, BLUE reached to a volume of 3393817 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about bluebird bio Inc. [BLUE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLUE shares is $7.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLUE stock is a recommendation set at 3.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for bluebird bio Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on August 05, 2022. The new note on the price target was released on August 02, 2022, representing the official price target for bluebird bio Inc. stock.

The Average True Range (ATR) for bluebird bio Inc. is set at 0.61, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 132.38. The Price to Book ratio for the last quarter was 3.99, with the Price to Cash per share for the same quarter was set at 1.61.

BLUE stock trade performance evaluation

bluebird bio Inc. [BLUE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.77. With this latest performance, BLUE shares gained by 1.04% in over the last four-week period, additionally plugging by 154.25% over the last 6 months – not to mention a drop of -18.19% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 52.75, with the RSI for the last a single of trading hit 50.27, and the three-weeks RSI is set at 53.67 for bluebird bio Inc. [BLUE]. The present Moving Average for the last 50 days of trading for this stock 7.04, while it was recorded at 7.98 for the last single week of trading, and 5.39 for the last 200 days.

bluebird bio Inc. [BLUE]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and bluebird bio Inc. [BLUE] shares currently have an operating margin of -15322.36 and a Gross Margin at -1000.66. bluebird bio Inc.’s Net Margin is presently recorded at -15364.23.

Return on Equity for this stock declined to -65.07, with Return on Assets sitting at -47.38.

bluebird bio Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.30.

Earnings per share (EPS) analysis for bluebird bio Inc. [BLUE] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLUE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for bluebird bio Inc. go to 56.40%.

bluebird bio Inc. [BLUE]: Insider Ownership positions

There are presently around $515 million, or 81.30% of BLUE stock, in the hands of institutional investors. The top three institutional holders of BLUE stocks are: STATE STREET CORP with ownership of 12,720,480, which is approximately 596.974% of the company’s market cap and around 1.20% of the total institutional ownership; BLACKROCK INC., holding 6,898,975 shares of the stock with an approximate value of $53.67 million in BLUE stocks shares; and TANG CAPITAL MANAGEMENT LLC, currently with $49.29 million in BLUE stock with ownership of nearly 7.188% of the company’s market capitalization.

Positions in bluebird bio Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 97 institutional holders increased their position in bluebird bio Inc. [NASDAQ:BLUE] by around 27,168,037 shares. Additionally, 63 investors decreased positions by around 16,602,004 shares, while 32 investors held positions by with 22,434,732 shares. The mentioned changes placed institutional holdings at 66,204,773 shares, according to the latest SEC report filing. BLUE stock had 36 new institutional investments in for a total of 5,486,526 shares, while 27 institutional investors sold positions of 4,412,077 shares during the same period.


Please enter your comment!
Please enter your name here